ReviewFood science & nutrition2025
Hyperhomocysteinemia-Driven Ischemic Stroke: Unraveling Molecular Mechanisms and Therapeutic Horizons.
Review in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of methylenetetrahydrofolate reductase C677T polymorphism with lacunar infarction: A systematic review and meta-analysis.Medicine · 2026Pooled it
- The MTHFR C677T polymorphism and protection against Legg-Calvé-Perthes disease in children: an updated systematic review and meta-analysis.Orphanet journal of rare diseases · 2026Pooled it
- Thrombosis and Anemia in Pediatric Inflammatory Bowel Disease: Pathophysiology, Clinical Impact and Future Directions.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Homocysteine is a toxic intermediate in the metabolism of methionine, and impaired homocysteine metabolism can lead to hyperhomocysteinemia, whose clinical relevance to ischemic stroke has been confirmed by many studies and is considered an independent risk factor for ischemic stroke. This article reviews and analyzes studies related to ischemic stroke due to hyperhomocysteinemia. Firstly, the mechanism of hyperhomocysteinemia was examined, and it was clarified that hyperhomocysteinemia is the result of mutations in the genes of key enzymes involved in homocysteine metabolism or nutritional disorders of cofactors involved in homocysteine metabolism. Secondly, we reviewed that hyperhomocysteinemia may lead to a series of pathological processes such as vascular injury, thrombosis, and vasoconstriction through the mechanisms of inflammation and oxidative stress, neurotoxicity, and epigenetic dysregulation, which ultimately lead to the development of ischemic stroke. The article also provides a review of research on the prevention and treatment of ischemic stroke associated with hyperhomocysteinemia, specifically describing three large clinical vitamin supplementation trials, which, despite the heterogeneity of findings, provide partial evidence for prevention. This review will provide some insights and thoughts for studying the biological mechanisms of hyperhomocysteinemia-associated ischemic stroke and exploring novel therapies for its prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.